AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 MAR 5 - (NewsRx.com & NewsRx.net) -- "Plaques containing beta-amyloid (A-beta) peptides are one of the pathological features of Alzheimer's disease, and the reduction of A-beta is considered a primary therapeutic target. Amyloid clearance by anti-A-beta antibodies has been reported after immunization, and recent data have shown that the antibodies may act as a peripheral sink for A-beta, thus altering the periphery/brain dynamics," researchers in the United States report.
"Here we show that peripheral treatment with an agent that has high affinity for A-beta (gelsolin or GM1) but that is unrelated to an antibody or immune modulator reduced the level of A-beta in the brain, most likely because of a peripherally acting effect," reported Yasuji Matsuoka and colleagues at New York University School of Medicine and Harvard Medical School. "We propose that in general, compounds that sequester plasma A-beta could reduce or prevent brain amyloidosis, which would enable the development of new ...
Source: HighBeam Research, Agents that target beta-amyloid show promise against Alzheimer's...